AG真人官方

Tingley Whittemore, Chief Medical Officer of Tenaya Therapeutics, Inc. (TNYA), reported three separate sales on 08/18/2025 to cover tax withholding for vested restricted stock units. Each sale was executed at a weighted average price of $1.253, with individual trade prices ranging from $1.18 to $1.32. The filings show dispositions of 1,608; 1,608; and 1,837 shares, leaving the reporting person with 176,248; 174,640; and 172,803 shares respectively after each transaction. The filing discloses remaining unvested RSUs that will result in future issuance: 103,132; 98,757; and 93,757 shares referenced in the explanatory footnotes. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.

Ali Faraz, who serves as Chief Executive Officer and a director of Tenaya Therapeutics, Inc. (TNYA), reported transactions dated 08/18/2025. The Form 4 discloses three separate sales of common stock executed to cover tax-withholding obligations arising from the vesting of restricted stock units (RSUs). The reported sales were 5,720, 3,893, and 4,920 shares at a weighted average sales price of $1.253, with executed prices ranging from $1.18 to $1.32. The filing lists the reporter's beneficial ownership following each transaction as 311,605, 307,712, and 302,792 shares, respectively, which include unvested RSUs of 243,943, 233,318, and 219,881 shares tied to the referenced awards. The form was signed by an attorney-in-fact.

Tenaya Therapeutics, Inc. (TNYA) filed a Form 144 notice for a proposed sale of 5,053 shares of its common stock through Morgan Stanley Smith Barney Operations Department, with an aggregate market value of $6,331.41. The filing lists total shares outstanding as 162,976,102 and an approximate sale date of 08/18/2025. The securities to be sold were acquired as Restricted Stock Units from the issuer on 08/18/2025, showing an acquired amount of 13,750 units and a payment date of 08/18/2025. The filer reports no sales in the past three months and includes the standard representation about nonpublic material information.

Tenaya Therapeutics, Inc. (TNYA) filed a Form 144 reporting a proposed sale of 14,533 shares of its common stock through Morgan Stanley Smith Barney, with an aggregate market value of $18,209.85. The filing lists the Nasdaq Global Select Market as the intended exchange and an approximate sale date of 08/18/2025.

The securities were acquired on 08/18/2025 as Restricted Stock Units from the issuer (total RSUs shown: 39,687), with payment listed as N/A. The filing states there were 162,976,102 shares outstanding and reports "Nothing to Report" for securities sold by the reporting person in the past three months. The notice includes the required representation that the signer is unaware of undisclosed material adverse information about the issuer.

Woodline Partners LP reports warrants convertible into 9,000,000 shares of Tenaya Therapeutics common stock. The filing states the reported warrants are exercisable into 9,000,000 shares and that, on a fully exercisable basis (but subject to contractual limits), those shares correspond to 4.99% of Tenaya's outstanding common stock based on 162,666,931 shares outstanding as of May 1, 2025. The reported voting and dispositive power numbers reflect the shares issuable upon exercise of the warrants.

The filing explains a contractual 4.99% exercise "Blocker" prevents exercise to the extent doing so would result in beneficial ownership above 4.99%, and the filer disclaims that this statement alone proves beneficial ownership for purposes of the Act.